Chilton Capital Management LLC Has $49 Million Holdings in Gilead Sciences, Inc. $GILD

Chilton Capital Management LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 441,459 shares of the biopharmaceutical company’s stock after buying an additional 68,610 shares during the period. Gilead Sciences makes up 1.6% of Chilton Capital Management LLC’s investment portfolio, making the stock its 19th largest holding. Chilton Capital Management LLC’s holdings in Gilead Sciences were worth $49,002,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. CFS Investment Advisory Services LLC boosted its stake in Gilead Sciences by 3.1% during the third quarter. CFS Investment Advisory Services LLC now owns 11,441 shares of the biopharmaceutical company’s stock worth $1,384,000 after acquiring an additional 348 shares in the last quarter. Purkiss Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 7.9% during the third quarter. Purkiss Capital Advisors LLC now owns 2,042 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 150 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in shares of Gilead Sciences by 2.6% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 199,160 shares of the biopharmaceutical company’s stock worth $22,116,000 after purchasing an additional 5,132 shares in the last quarter. Sage Rhino Capital LLC increased its position in Gilead Sciences by 213.7% in the 3rd quarter. Sage Rhino Capital LLC now owns 7,400 shares of the biopharmaceutical company’s stock valued at $821,000 after buying an additional 5,041 shares in the last quarter. Finally, EWA LLC increased its position in Gilead Sciences by 3.3% in the 3rd quarter. EWA LLC now owns 2,841 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 90 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $137.78 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market cap of $170.94 billion, a PE ratio of 21.36, a P/E/G ratio of 0.71 and a beta of 0.33. The business has a 50 day moving average of $124.25 and a 200-day moving average of $118.88. Gilead Sciences, Inc. has a 12-month low of $93.10 and a 12-month high of $138.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 247,397 shares of company stock worth $31,986,612 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. Needham & Company LLC increased their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Truist Financial initiated coverage on shares of Gilead Sciences in a research report on Monday, November 24th. They issued a “buy” rating and a $140.00 price target for the company. Citigroup upped their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. TD Cowen raised their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $134.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.